Pharma deals indicate promise of RNAi therapeutics

07/24/2008 | InPharm.com

Novartis has extended its collaboration with Alnylam Therapeutics and Roche has purchased gene-silencing specialist Mirus Bio Corp., an indication that the drug industry recognizes the research and commercial possibilities in RNAi-based therapeutics for a range of diseases. A Novartis official said RNAi "holds great potential," adding, "In particular, this new area of biology has potential to treat diseases that have not been able to be addressed by traditional approaches."

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC